Drug Repurposing Market Expected to Surpass USD $53.42 Billion by 2029, Expanding at 9.3% CAGR

 Get 20% Off Market Intelligence Reports With Code ONLINE20 — Track Global Tariffs, Economic Shifts, and Sector Transformations

 

 What Is the Growth Potential of the Drug Repurposing Market in the Next Decade?
 The drug repurposing market size has grown strongly in recent years. It will grow from $34.12 billion in 2024 to $37.38 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to the rising cost of novel drug development, increasing drug failures in clinical trials, a rise in demand for faster drug approval, increasing availability of off-patent drugs, and rising government and academic research funding.
 
 The drug repurposing market size is expected to see strong growth in the next few years. It will grow to $53.42 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing demand for cost-effective therapies, growing investments from pharmaceutical companies, increasing collaborations among biotech firms, and expanding applications in oncology and neurology. Major trends in the forecast period include advancements in computational drug discovery tools, advanced use of AI and ML in drug repurposing, innovation in predictive modeling for drug efficacy, integration of big data analytics in drug screening, and advancements in biomarker identification.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=25758&type=smp
 
 What Are the Key Market Drivers and Opportunities in the Drug Repurposing Market?
 The growing prevalence of neurodegenerative diseases is expected to propel the growth of the drug repurposing market going forward. Neurodegenerative diseases refer to a group of disorders characterized by the progressive loss of structure or function of neurons, including their death. The rise in neurodegenerative diseases such as alzheimer’s dementia is due to increased life expectancy, as aging is the primary risk factor that contributes to the gradual decline of neuronal function over time. Drug repurposing helps neurodegenerative diseases by identifying existing drugs with known safety profiles that can be redirected to target disease pathways, accelerating the development of effective treatments. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, in 2023, about 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, with projections indicating an increase to 13.8 million by 2060. Therefore, the growing prevalence of neurodegenerative diseases is driving the growth of the drug repurposing market.
 
 What Are the Key Segments in the Drug Repurposing Market?
 The drug repurposing market covered in this report is segmented — 
 
 1) By Type: Disease-Centric, Target-Centric, Drug-Centric
 2) By Drug Molecules: Biologics, Small Molecule
 3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders
 4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular
 5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations
 
 Subsegments:
 1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing
 2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting
 3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing
 
 Which Trends Are Expected to Redefine the Drug Repurposing Market Landscape?
 Major companies operating in the drug repurposing market are focusing on developing advanced technologies such as artificial intelligence (AI)-powered drug-protein interaction modeling to accelerate the identification of new therapeutic uses for existing drugs. Artificial intelligence (AI)-powered drug-protein interaction modeling leverages artificial intelligence and machine learning to predict how drugs interact with proteins across the human proteome, using expansive datasets to enhance accuracy and confidence. For instance, in July 2025, Cosmos Health Inc., a US-based healthcare company, unveiled Cloudscreen 2.0, an advanced AI platform for drug repurposing. It is a next-generation system designed to process datasets over 100 times larger than before, enabling comprehensive analysis of drug-protein interactions. By incorporating mutagenesis data and tools for analyzing disordered proteins, the platform targets diseases such as cancer, obesity, and diabetes. Additionally, graphics processing unit (GPU)-based cloud computing empowers scalable processing, making the platform a critical innovation in accelerating research and development pipelines for drug repurposing across multiple therapeutic areas.
 
 Who Are the Top Competitors in the Drug Repurposing Market?
 Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , International Business Machines Corporation (IBM), Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Alnylam Pharmaceuticals Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Cosmos Health Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc. 
 
 Get the full drug repurposing market report here:
 https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report
 
 Which Regions Offer the Highest Potential for Drug Repurposing Market Expansion?
 North America was the largest region in the drug repurposing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company